DPP4 Inhibitors
1 drugsAbout DPP4
Dipeptidyl peptidase-4 (DPP4) is a protein involved in glucose metabolism, making it a target for metabolic disorders. It modulates glucose levels, influencing therapeutic interventions for conditions like type 2 diabetes.
Currently, there is no genetic evidence directly linking DPP4 to specific diseases. However, the existence of an approved drug suggests a clinically relevant mechanism of action.
DPP4 is targeted by one FDA-approved drug, SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE, a small molecule. This drug, marketed by Dr. Reddy's, has three indications in the metabolic therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Healthy Subjects with only 5 trials.
Human Genetic Evidence Strong
There is no genetic evidence data available for this target.
Absence of genetic validation increases the risk of clinical trial failure; consider investing in genetic studies.
Evidence Across Diseases
20 totalGWAS and other genetic studies link DPP4 to 23 diseases.
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for DPP4 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Drugs
Dr. Reddy's is the only company with an approved DPP4-targeting drug.
High market concentration suggests potential entry barriers; consider strategic partnerships to overcome them.
Clinical Trials 977 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 244 | 194 | 21 | 28 | 90% |
| Phase 2 | 270 | 142 | 62 | 65 | 70% |
| Phase 3 | 227 | 183 | 15 | 27 | 92% |
| Phase 4 | 236 | 172 | 30 | 32 | 85% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 3 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 506 clinical trials targeting DPP4.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities